Vaxcyte (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 10,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $53.89, for a total value of $538,900.00. Following the completion of the transaction, the chief financial officer directly owned 105,176 shares of the company’s stock, valued at approximately $5,667,934.64. The trade was a 8.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, July 6th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The shares were sold at an average price of $57.28, for a total value of $572,800.00.
• On Thursday, June 18th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The stock was sold at an average price of $53.00, for a total value of $530,000.00.

Vaxcyte Price Performance

Vaxcyte stock opened at $55.92 on Thursday. The business has a 50 day moving average of $53.56 and a 200-day moving average of $55.10. The company has a market capitalization of $8.07 billion, a P/E ratio of -8.13 and a beta of 1.23. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same quarter last year, the company earned ($1.22) EPS. Equities analysts anticipate that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Vaxcyte News Roundup

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss was narrower than expected: Vaxcyte reported second-quarter EPS of negative $1.97, beating the consensus estimate of negative $2.06. Although the loss widened from negative $1.22 a year earlier, the earnings beat likely helped sentiment. Vaxcyte quarterly earnings release
• Positive Sentiment: Important VAX-31 trial updates are approaching: Topline safety, tolerability and immunogenicity data from the adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from the OPUS-2 and OPUS-3 trials are expected in the first half of 2027, giving investors several potential catalysts. Vaxcyte second-quarter 2026 business update
• Positive Sentiment: Strong liquidity reduces near-term financing risk: Vaxcyte had approximately $2.5 billion in cash, cash equivalents and investments as of June 30, 2026, providing substantial funding for its late-stage vaccine programs and development of VAX-A1.
• Neutral Sentiment: Analyst consensus remains cautious: Brokerages recently assigned Vaxcyte a consensus “Hold” rating, suggesting that valuation, clinical execution and the company’s ongoing losses remain areas of investor concern. Vaxcyte consensus rating report
• Negative Sentiment: Several executives sold shares: The CFO, COO and another insider sold a combined 29,250 shares for approximately $1.6 million. Each transaction was conducted under a pre-arranged Rule 10b5-1 plan, which reduces the significance of the sales but may still weigh modestly on sentiment.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Finally, Zacks Research lowered Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $86.00.

Institutional Trading of Vaxcyte

Several hedge funds have recently modified their holdings of PCVX. EverSource Wealth Advisors LLC boosted its holdings in shares of Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares during the last quarter. Meeder Advisory Services Inc. increased its holdings in Vaxcyte by 2.9% during the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock worth $484,000 after buying an additional 231 shares during the last quarter. CWM LLC raised its position in Vaxcyte by 9.0% in the fourth quarter. CWM LLC now owns 2,840 shares of the company’s stock worth $131,000 after acquiring an additional 234 shares during the period. Principal Financial Group Inc. raised its position in Vaxcyte by 7.0% in the first quarter. Principal Financial Group Inc. now owns 5,275 shares of the company’s stock worth $307,000 after acquiring an additional 343 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.